Evidence map›Paper›PMID 33263173›Full record

ArticleJournal of clinical immunology2021

Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency.

Samaneh Delavari, Hassan Abolhassani, Farhad Abolnezhadian, Fateme Babaha, Sara Iranparast, Hamid Ahanchian, Nasrin Moazzen, Mohammad Nabavi, Saba Arshi, Morteza Fallahpour and 19 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of clinical immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 4 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 4 syntheses or guidelines pooled it, 129 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. COVID-19 in Pediatric Patients with and Without Immunocompromised.Medical journal of the Islamic Republic of Iran · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Observational
  20. Severity of SARS-CoV-2 infection in children with inborn errors of immunity (primary immunodeficiencies): a systematic review.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023
    Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 13 institutions in 2 countries.

Samaneh Delavari *Research Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Hassan Abolhassani *Research Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. hassan.abolhassani@ki.se.ORCID 0000-0002-4838-0407
Farhad AbolnezhadianDepartment of Pediatrics, Abuzar Children's Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Fateme BabahaResearch Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Sara IranparastDepartment of immunology, Faculty of Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Hamid AhanchianAllergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Nasrin MoazzenAllergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad NabaviDepartment of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Saba ArshiDepartment of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Morteza FallahpourDepartment of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Mohammad Hassan BemanianDepartment of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Sima ShokriDepartment of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Tooba MomenDepartment of Allergy and Clinical Immunology, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Noncommunicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
Mahnaz Sadeghi-ShabestariImmunology research center of Tabriz, TB and lung research center of Tabriz, children hospital, Tabriz University of Medical Science, Tabriz, Iran.
Rasol MolatefiDepartment of Pediatrics, Bo-Ali Children's Hospital of Ardabil University of Medical Sciences, Ardabil, Iran.
Afshin ShirkaniAllergy and Clinical Immunology Department, Bushehr University of Medical Sciences, School of Medicine, Bushehr, Iran.
Ahmad VosughimotlaghDepartment of Pediatrics, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Molood SafariradDepartment of Pediatrics, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Meisam SharifzadehDivision of Pediatric Critical Care, Children Medical Center, Tehran University of Medical Science, Tehran, Iran.
Salar PashangzadehResearch Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Fereshte SalamiResearch Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Paniz ShirmastResearch Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Arezou RezaeiResearch Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Tannaz Moeini ShadResearch Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Minoo MohrazIranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
Nima RezaeiResearch Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Lennart HammarströmDivision of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Sweden.
Reza YazdaniResearch Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Asghar AghamohamamdiResearch Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. aghamohammadi@tums.ac.ir.
Children's Medical Center · IRIran University of Medical Sciences · IRAhvaz Jundishapur University of Medical Sciences · IRKarolinska University Hospital · SEMashhad University of Medical Sciences · IRNorth Khorasan University of Medical Sciences · IRArdabil University of Medical Sciences · IRBushehr University of Medical Sciences · IRIranian Institute for Health Sciences Research · IRIsfahan University of Medical Sciences · IRTarbiat Modares University · IRUniversity of Tabriz · IRUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although it is estimated that COVID-19 life-threatening conditions may be diagnosed in less than 1:1000 infected individuals below the age of 50, but the real impact of this pandemic on pediatric patients with different types of primary immunodeficiency (PID) is not elucidated. The current prospective study on a national registry of PID patients showed that with only 1.23 folds higher incidence of infections, these patients present a 10-folds higher mortality rate compared to population mainly in patients with combined immunodeficiency and immune dysregulation. Therefore, further management modalities against COVID-19 should be considered to improve the survival rate in these two PID entities using hematopoietic stem cell transplantation and immunomodulatory agents.

Indexed as

Health Impact AssessmentSARS-CoV-2Child, PreschoolClinical Decision-MakingComorbidityCOVID-19Disease ManagementFemaleHumansInfantMaleMortalityPrimary Immunodeficiency DiseasesPublic Health SurveillanceSeverity of Illness IndexCOVID-19Mortality ratePrimary immunodeficiencySevere viral infection

Identifiers

PMID33263173
PMCPMC7707812
OpenAlexW3109136263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.